Skip to content

Author

A. Labate

We have 3 of 53 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Beyond seizure control: Non-seizure-related outcomes in focal-onset epilepsy treated with adjunctive cenobamate. Third interim results from the BLESS study.

OBJECTIVE Cenobamate is approved for treatment of focal seizures in adults, but evidence on non-seizure outcomes remains limited. This interim statistical analysis of the cenoBamate in aduLts with focal-onsEt SeizureS (BLESS) study evaluated patient- and clinician-reported outcomes for up to 52 weeks of cenobamate trea...

Simona Lattanzi, G. d'Orsi, M. T. Di Claudio et al. · 0 citations
Oct 2026

Reduction of interleukin-6 levels in patients with Friedreich's Ataxia treated with omaveloxolone.

Omav confirmed a favorable safety and tolerability profile in adult patients with FRDA in a real-world setting after 48 weeks of treatment, and a sustained reduction in IL-6 levels supports a potential direct immunomodulatory effect of the drug, consistent with its proposed disease-modifying activity.

V. Di Stefano, Salvatore Maria Lima, S. Campo et al. · 0 citations
Sep 2026

Toward harmonized reporting of Alzheimer’s disease biomarkers in clinical practice

The principles of harmonized reporting for Alzheimer’s disease biomarkers and a structured framework for standardized clinical neurochemistry reports are discussed and a structured framework for standardized clinical neurochemistry reports is proposed.

L. Agnello, Andrea Pilotto, L. Gaetani et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.